key: cord-0320041-7j58hw61
authors: Gómez-Carballa, Alberto; Rivero-Calle, Irene; Pardo-Seco, Jacobo; Gómez-Rial, José; Rivero-Velasco, Carmen; Rodríguez-Núñez, Nuria; Barbeito-Castiñeiras, Gema; Pérez-Freixo, Hugo; Cebey-López, Miriam; Barral-Arca, Ruth; Rodriguez-Tenreiro, Carmen; Dacosta-Urbieta, Ana; Bello, Xabier; Pischedda, Sara; Currás-Tuala, María José; Viz-Lasheras, Sandra; Martinón-Torres, Federico; Salas, Antonio
title: A multi-tissue study of immune gene expression profiling highlights the key role of the nasal epithelium in COVID-19 severity
date: 2021-10-29
journal: bioRxiv
DOI: 10.1101/2021.10.27.466206
sha: 177fa558c059bda0573cb61c6d3ea40ccff529d9
doc_id: 320041
cord_uid: 7j58hw61

Background COVID-19 symptoms range from mild to severe illness; the cause for this differential response to infection remains unknown. Unravelling the immune mechanisms acting at different levels of the colonization process might be key to understand these differences. Methods and findings We carried out a multi-tissue (nasal, buccal and blood; n = 156) gene expression analysis of immune-related genes from patients affected by different COVID-19 severities, and healthy controls through the nCounter technology. We then used a differential expression approach and pathways analysis to detect tissue specific immune severity signals in COVID-19 patients. Mild and asymptomatic cases showed a powerful innate antiviral response in nasal epithelium, characterized by activation of interferon (IFN) pathway and downstream cascades, successfully controlling the infection at local level. In contrast, weak macrophage/monocyte driven innate antiviral response and lack of IFN signalling activity were shown in severe cases. Consequently, oral mucosa from severe patients showed signals of viral activity, cell arresting and viral dissemination to the lower respiratory tract, which ultimately could explain the exacerbated innate immune response and impaired adaptative immune responses observed at systemic level. Results from saliva transcriptome suggest that the buccal cavity might play a key role in SARS-CoV-2 infection and dissemination in patients with worse prognosis. Conclusions We found severity-related signatures in patient tissues mainly represented by genes involved in the innate immune system and cytokine/chemokine signalling. Local immune response could be key to determine the course of the systemic response and thus COVID-19 severity. Our findings provide a framework to investigate severity host gene biomarkers and pathways that might be relevant to diagnosis, prognosis, and therapy.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 19 , was first identified in patients suffering from a respiratory disease in Wuhan (Hubei province, China) in December 2019 (1, 2). Soon after, SARS-CoV-2 quickly spread across multiple countries, reaching high frequencies in some geographic regions favored by two main catalyzers, namely variants showing higher transmissibility (3) and superspreading events (4) (5) (6) . To date, the SARS-CoV-2 pandemic has caused >3.8M deaths and >175M confirmed cases worldwide (www.who.int; 15-06-2021). SARS-CoV-2 is primarily transmitted by airway droplets; the nasal epithelium has been postulated as the main portal of entrance and transmission of the virus, and the location where higher viral loads and replication rates were observed (7) (8) (9) .

COVID-19 is mainly characterized by producing influenza-like symptoms, and other (e.g., gastro-intestinal) non-related complications (10, 11) . A wide range of symptoms have been described, from absolutely no symptoms to severe pneumonia, lung damage, and progressive respiratory failure (12) .Investigating the immunological processes underpinning SARS-CoV-2 pathogenesis is key for the development of efficient therapeutic strategies and vaccines against COVID-19. The immune system dysregulation described in severe patients is characterized by a reduce number of lymphocyte T subpopulations CD4+ and CD8+, pointing to an absence of T-cell specific response (13) (14) (15) . Impairment of the adaptative immune system, together with a non-effective host immune response by innate cells, could be the cause of a higher viral replication and the activation of inflammatory processes, resulting in tissue damage and a more severe disease course (13, 16) . The hyper-inflammatory response occurring during the acute phase is mainly driven by the monocyte-macrophage activation (17) , the release of pro-inflammatory cytokines (13, 18, 19) and increase of other mediators e.g. ferritin and C-reactive protein (CRP). The infiltration of monocytes-derived macrophages from blood points to these cells as the main cause of the lung tissue damage in severe cases (16).

Analysis of blood gene expression of immune-related genes has allowed to shed light on the immune response to pathogen infection. In COVID- 19, results from transcriptomic studies conducted on peripheral blood mononuclear cells (PBMCs) indicate that genes associated with inflammatory and hypercoagulability pathways (20) , and the imbalance between innate and adaptive immune responses, are the main factors responsible for severe disease course (21) . Immune gene expression analysis carried out in serial whole blood from three patients with mild, moderate, and severe disease (22) most of the studies were carried out in vitro or nasal-derived epithelial cells (7, (25) (26) (27) . Only a few studies were performed on naso-pharyngeal (NP) swabs of infected patients; the results point to different expression patterns depending on the viral load, age, and sex (28). Comparison of expression profiles of infected adults and children (29) indicates an early and more efficient innate immune response in nasal mucosa from children, thus conditioning the final outcome of the disease. So far, only one study undertaken in three severe patients has proposed candidate transcripts for severity and disease outcome in NP samples (30) . Saliva has also been proposed as a good alternative to NP swabs for SARS-CoV-2 detection through a non-invasive approach (31-33), since it is easier to collect and yield comparable results (34) . The study of the specific host gene expression profile produced by the SARS-CoV-2 infection in oral mucosa has not raised comparable interest; there are only a few in-silico predictive studies using retrospective available data from non-infected subjects (35, 36) , and a recent study (37) highlighting the importance of the oral cavity in the viral transmission and dissemination.

We carried out a multi-source gene expression study at three different transcriptomic layers, using blood, nasal and saliva samples, collected on asymptomatic, mild, and severe patients. Our study aims at understanding the differential immune response that leads to different disease severities, and finding specific biomarkers of severity to improve patient management and prognostic prediction.

We prospectively collected blood, saliva, and nasal epithelium samples from 52 COVID-19 patients with confirmed PCR-positive diagnosis of SARS-CoV-2 infection in the Hospital Clínico Universitario of Santiago de Compostela (Galicia; Spain) from March to June 2020. Patients and healthy controls were self-reported as of South-European ancestry; and cases were classified at the time of sample collection by severity illness: severe (ICU admission), moderate (non-ICU but admitted to hospital) and mild (domiciliary lockdown patients with mild symptoms or asymptomatic; herein mild patients). Comparisons were carried out as follows:

(i) whole blood from 41 patients and 13 controls, (ii) nasal epithelium from 38 patients and 11 controls, and (iii) saliva from 41 patients and 12 controls. The complete tissue sample set could be collected for 27 out of the 52 patients.

Demographic and clinical data from the patients are summarized in Table 1 (see S1 

Blood, nasal epithelium, and saliva samples were sampled from patients and controls at the same timepoints. Blood samples (2.5ml) were collected in PAXgene tubes (BD). RNA was isolated using PAXgene blood miRNA extraction kit (Qiagen) following manufacturer recommendations and carrying out the oncolumn DNase I treatment during the extraction process. Saliva and nasal epithelium samples were collected in Oragene CP-190 kit (DNA Genotek). We used sponges (SC-2 kit from DNA Genotek) to assist saliva collection in ICU patients unable to spit. RNA from saliva and nasal epithelium specimens was isolated using 500µl of sample and the RNeasy microkit (Qiagen). We used Oragene RNA neutralizer solution (DNA Genotek) to precipitate impurities and inhibitors and slightly modified the protocol provided by the extraction kit as recommended by the Oragene tubes supplier. After isolation, RNA amount and integrity was checked using TapeStation 4200 (Agilent), and DV200 values were calculated to both ensure that >50% of the of the RNA fragments were above 200nt and estimate the optimal sample input for the nCounter analysis. Universal Transport Medium tubes (UTM) nasopharyngeal samples were collected to check for the presence as well as the viral load of SARS-CoV-2 at the same time as collection of blood, saliva, and nasal epithelium samples. Molecular detection of viral particles was performed through a multiplex real-time PCR using the Allplex™SARS-CoV-2 Assay (Seegene).

Nanostring nCounter expression assay Immunological gene expression patterns of different tissues from COVID-19 patients and controls were evaluated through the SPRINT nCounter system (NanoString Technologies) and the Immunology Panel (594 genes involved in several immunological processes). This panel covers the main immunological routes, including major classes of cytokines and their receptors, chemokine ligands and receptors, IFNs and their receptors, the TNF-receptor superfamily, and the KIR family genes. We used the standard gene expression protocol for 12x RNA hybridization with 5µl of RNA as input, a hybridization time of 18h for all samples and mixing control and COVID-19 samples to avoid technical sample bias. We first carried out a quality control (QC) of the raw data checking some technical parameters following manufacturer recommendations to verify the absence of technical problems. Samples that did not pass technical QC, or with low number of genes detected, were excluded for downstream analysis.

For the longitudinal multi-tissue experiment, normalization of the gene expression data was carried out for each tissue separately by selecting the optimal number and best reference candidate from the set of housekeeping (HK) genes included in the panel, as well as other endogenous genes that showed high levels of stability between samples. The GeNorm algorithm (38) implemented in the R package CrtlGene (39) was used to test for the most stable and optimal number of genes for normalization. We excluded HK candidate genes with less than 50 raw counts in any of the samples compared from the reference selection analysis.

Data normalization was performed through a combined approach using both DESeq2 (40) and RUVSeq (41) as described in (42) . Genes with counts below the background (mean + 2 standard deviations (SD) of the negative control spikes in the code set) were not included in the differential expression (DE) analysis.

After data normalization and background thresholding, we eliminated lower expressed genes from the list of DEG, retaining a total of 495 genes in blood samples, 544 genes in nasal epithelium samples and 545 genes in saliva samples for downstream analysis. DEG between cohorts were obtained using DESeq2 (40) . We used age and sex as covariables to correct the model. Volcano plots and heatmaps were built with EnhancedVolcano (43) and ComplexHeatmap (44) R packages, respectively. All graphics were created using R (www.rproject.org) software and the ggplot2 package (45) . Wilcoxon test was used to assess statistical significance between patient groups, and Spearman test for the correlation indices. We focused on highly statistically significant expression changes by considering as thresholds an adjusted P-value < 0.05, and log2FC ³ |1.5| for downstream analysis. For the transversal multi-tissue experiment we sub-selected 21 patients for which samples from the three tissues were available (mild: n = 11; severe: n = 10). We employed a complex model design including the tissue/severity interaction to find tissue-specific severity effects. As reference for the analyses, we used blood and the mild category. We followed the same procedure as in the longitudinal analysis but data from the three tissues were normalized together after selecting a set of adequate reference genes.

We followed both over-representation (ORA) and gene-set enrichment (GSEA) (46) approaches to identify biological functions, cellular components and pathways related to the differences in gene expression. For ORA we used the DEG as input (threshold: log2FC ³ |1.5|), and the genes included in the expression panel as pool for statistical calculations. For GSEA we used all available molecular measurements (log2FC) from the genes included in the DE to detect coordinated changes in the expression of genes from same pathway.

Analyses were carried out using the Clusterprofiler (47) R package. We applied the Benjamini-Hochberg (H-B) procedure for multiple test correction and thresholds were set to 0.05. We tested both the GO (Gene Ontology) and

Reactome databases. Graphics were obtained with the R package enrichplot (48) .

We used three additional datasets to validate and check the specificity of the healthy controls and bacterial vs. healthy controls, we first normalized and preprocessed each dataset separately using Lumi (55) for Illumina® microarrays data and Oligo (56) for Affymetrix® datasets, while RNA-seq data were preprocessed as described previously (57) . Then, we merged these databases retaining only the common genes. Subsequently, we used the R package COCONUT to combine all datasets into one and reduce batch effects in the metaanalysis (58) . Next, we used Limma package (59) to detect DEG and calculate log2FC values between groups. Scatterplots of log2FC values and Pearson correlation indexes were obtained for the pseudo-validation analysis.

We imputed immune cell subset abundances from nCounter expression data in different patient categories, including mild and healthy controls, from which real immune cell counts from blood tests were not available. We used the CIBERSORTX (60) tool and a leukocyte gene signature matrix (61) obtained from microarray data as reference. We applied a B-mode batch correction to account for cross-platform variation and 500 permutations for the analysis. We graphically represented immune cell proportions using R software and carried out a Wilcoxon test to assess statistical significance between categories.

Expression data that support the findings of the present study have been deposited in Gene Expression Omnibus (GEO) database under the accession code GSE183071.

Most of the clinical features were only available for hospitalized patients ( Table   1) . Similar median symptoms days to sampling were obtained for mild, moderate, and severe cases, as well as admission days to sampling in the case of moderate and severe patients (P-value = 0.236 and 0.704, respectively). During admission, oxygen support was required for 64.3% of the moderate cases and 100% of the severe cases (78.6% required invasive ventilation). All moderate cases were treated with a double therapy including antibiotic and antimalarial drugs (in 78.6% of the moderate cases, antiviral therapy was also administrated). Severe cases received a combined triple therapy of antibiotic, antiviral (lopinavir and ritonavir) and antimalarial (hydroxychloroquine) treatment, and 46.6% of them received tocilizumab.

No statistical differences were observed in viral loads at the time of sample collection depending on COVID-19 severity, nor statistical correlation between days of symptoms to sample collection and Ct values from the SARS-CoV-2 qPCR assay (S1A Fig in S1 Appendix) on nasopharyngeal swabs obtained at the point of sample collection. However, we obtained statistically significant differences in some analytical parameters between severe and moderate cases at the sampling timepoint: higher neutrophil counts (P-value = 0.012), ferritin (Pvalue = 0.002), D-Dimer (P-value = 0.006) and lactate (P-value = 0.019) values, but lower lymphocyte counts (P-value = 0.002) and fibrinogen (P-value = 0.004) values in severe cases. Maximum values for C-reactive protein (CRP) and neutrophils (P-values = 0.02 and 0.006, respectively) and minimum values for lymphocytes (P-value < 0.001) also showed statistically significant differences between these groups.

Immune cell fractions inferred from gene expression data also pointed to a significantly lower proportion of T lymphocyte subpopulations CD4 and CD8 in severe cases than in other severity categories and healthy controls (S1B Fig in S1 Appendix). Likewise, the proportion of B cells was significantly higher in mild when compared to moderate and severe cases. Cell numbers of CD4 and NK subpopulation also showed a significant decrease with disease severity. Finally, a higher proportion of monocytes was also observed in moderate cases, correlating well with real monocyte counts detected in the blood tests from moderate and severe cases.

Principal component analysis (PCA) of blood gene expression revealed a moderate differentiation by severity in the first principal component (PC1; Fig   1A) . When we compared the whole COVID-19 cohort against controls we obtained nine DEG (S2 Table, We performed a more detailed analysis of the immunological processes underlying COVID-19 by comparing different severities (Fig 1B; Fig 1C; S4 Fig in S1 Appendix). We found a similar number of DEG when comparing severe cases vs. healthy controls and severe vs. mild patients (28 and 30 respectively; S2 Table; Fig 1D) , pointing to a limited systemic immune response (Fig 1D; S4 Fig in S1 Appendix). We found 14 common DEG in all comparisons involving severe cases (Fig 1D) ; ARG1 gene was the most remarkable one over-expressed in severe cases (Log2FC = 3.98 -4.71; adjusted P-value = 1.53E-18 Table) . Other significatively over-expressed genes in severe cases were those related to pro-inflammatory pathways IL-1 (IL1R1 and IL1R2) and IL-18 (IL18R1) and immunoregulatory functions (FKBP5 and S100A8); S5 Fig in S1 Appendix. To further test this 14-transcript COVID-19 signature for severe patients, we compared our results to an independent cohort (24); after excluding two genes (ZBTB16 and IL1RL1) that were not found to be DE between their severe cases vs. healthy controls (24), we found a notable correlation showed an increased expression in mild (log2FC = 2.10; adjusted P-value= 1.32E-5) and moderate cases (log2FC = 1.78; adjusted P-value = 5.59E-5) respectively, with respect to controls (S2 Table) . When comparing DEGs between hospitalized and non-hospitalized patients, the most relevant genes were CAMP, LTF, CEACAM8 and CEACAM6, all involved in neutrophil degranulation processes triggered by the innate immune response (S6 Fig in S1 Appendix).

Pathway analysis by way of a GSEA of severe cases vs. healthy controls and using Reactome revealed: (i) an up-regulation of innate immune processes (mainly driven by neutrophil activation and degranulation, the IL-1 pathways, and the TLR cascade (S3 Table, Table, S7 Fig in S1 Appendix). Similar findings were observed in comparisons of severe vs. moderate (S3 Table, S8 Fig in S1 Appendix) and severe vs. mild cases (S3 Table, Table, S10 Fig in S1 Appendix) . Overall, there exists a significant upregulation of the neutrophil activation and degranulation pathways, which increase with severity, and a lack of IFN response in severe cases. The differential neutrophil-driven immune response observed in moderate and severe patients is also detected when comparing hospitalized against non-hospitalized cases and healthy controls (S11 Fig in S1 Appendix; S3 Table) . Fig 2B) . Conversely, mild and moderate cases show more remarkable differences with severe and controls in the PC1 dimension (23% of the variation).

Of the seven DEGs observed in the comparison patients vs. healthy controls, one is under-expressed and six over-expressed (S4 Table; Fig 2C) . Thus, FCER1A is under-expressed in patients when compared against controls (log2FC = -1.63;

adjusted P-value = 0.004; severe vs. controls: log2FC = -3.28; adjusted P-value = 2.75E-9; severe vs. moderate: log2FC = -2.01; adjusted P-value = 0.0004; severe vs. mild: log2FC = -1.96; adjusted P-value = 0.00097), even though it was not detected as DE when comparing moderate and mild cases with healthy controls (S4 Table; however the absolute expression values showed only weak statistical significance in mild and moderate patients vs. healthy controls; Fig 2D) .

Of the over-expressed genes, SERPING1 gene leads the DEG list; the main signal comes from the high expression levels observed in moderate and mild patients against controls; this gene was however not DE in severe cases when compared with controls. Thus, SERPING1 over-expression decreased gradually from mild to severe disease (S4 Table; Fig 2D) . A similar pattern was observed for other genes (CXCL9, LAG3 and GZMB), all showing a gradual overexpression in moderate and mild cases against controls (S4 Table; both categories vs. controls, but no DEG when comparing mild vs. moderate cases (Fig 2C; S13 Fig in S1 Appendix; S14 Fig in S1 Appendix) . Despite the similarities in immune response of both phenotypic categories, these genes showed a gradual increase in expression from severe to mild disease; the differences were found to be more notable when comparing mild vs. controls than in moderate vs. controls (S4 Table) .

The comparison of severe vs. controls/moderate/mild yielded 18, 19 and 27 DEGs genes, respectively (Fig 2C; S4 Table) ; eight genes are shared between these three comparisons (FCER1A, IL18R1, IL1R2, CCL3 CCL4, CLEC4E, CD163 and MARCO), all over-expressed in severe cases (except FCER1A) and all mainly involved in the innate immune and inflammatory response (S15 Fig in S1 Appendix) . IL18R1 and IL1R2 appeared in the top three most DEGs in severe cases compared to all categories, with a log2FC ~2 in severe vs. moderate cases, and even higher in severe vs. controls/mild cohorts.

Other under-expressed genes in severe compared to mild/moderate cases included IFIT2 (Interferon Induced Protein with Tetratricopeptide Repeats 2) and IDO1, whose encoded protein is produced in response to inflammation and has autoimmune protective features (S4 Table; We did not find statistically significant pathways in the nasal samples from severe cases vs. controls using both GSEA and ORA. Moderate vs. controls comparisons highlighted some up-regulated pathways in GSEA mainly connected to interaction and response to other organism processes (S5 Table) , and inhibition of endopeptidase activity (S16 Fig in S1 Appendix) . Comparison of mild cases vs. controls using ORA suggested two main processes: (i) antimicrobial immune humoral response (an adaptative immune response mainly driven by B lymphocytes), and (ii) chemokine related pathways (S5 Table; Table) , a regulator of infection and inflammation. Molecular functions showing down-regulation in severe vs. mild cases were MHC protein binding and hydrolase activity (S18 Fig in S1 Appendix) . ORA analysis of DEGs revealed alterations in chemokine dynamics-related pathways, with overexpression of CC-type chemokines and MARCO, and under-expression of CXCtype chemokines and DEFB4A (S18 Fig in S1 Appendix) . The comparison of severe vs. moderate patients using GSEA analysis showed some similarities with that of severe vs. mild cases (S19 Fig in S1 Appendix) . Reactome Table) .

Among the genes detected in saliva samples, there was no DEG when comparing patients and healthy controls. This fact is reflected in a PCA (and heatmap analysis), which shows a large cluster with overlapping controls, mild and moderate, and only slightly differentiation of the severe cases in the PC1 (35% of the variation) and the PC2 (20% of the variation); Fig 3A,D . Therefore, the data seem to indicate very limited immune response to infection in the oral cavity of mild and moderate patients. A few DEGs were detected when comparing hospitalized with non-hospitalized patients (Fig 3B; S21 Fig in S1 Appendix) and against controls (S6 Table) . As expected, most DEGs are the same in both comparisons, with 11 out of the 12 DEGs detected in hospitalized vs. nonhospitalized cases also appearing in hospitalized vs. controls, all of them overexpressed (S21 Fig in S1 Appendix; S6 Table) . The strongest differences in hospitalized vs. non-hospitalized patients were represented by (i) PLAU, a gene encoding a secreted serine endopeptidase that transforms plasminogen in plasmin and is implicated in the rearrangement of extracellular matrix and cell migration, and (ii) LGALS3, which plays a role in apoptosis, innate immunity (attracting macrophages and activating neutrophils), cell adhesion and T-cell regulation processes as well as in acute inflammatory responses (Fig 3C) . These two genes were the only ones detected as DE when comparing moderate vs. mild cases; they probably constitute the strongest and most specific immune signature in oral mucosa from hospitalized individuals (S6 Table; S22 Fig in S1 Appendix). The other DEGs of the signature from hospitalized samples also exhibited expression levels that increased with severity (S22 Fig in S1 Appendix).

We found 18 common over-expressed DEGs that differentiate severe cases from the other phenotypic categories (Fig 3E; S23 Fig in S1 Appendix) .

CCL20 showed the highest log2FC value in all comparisons (S6 Table) . As expected, higher differences were found in severe vs. mild and severe vs. controls (Fig 3E) . Eleven out of the 18 genes were also included in the signature that differentiated hospitalized from both non-hospitalized and healthy controls, respectively (Fig 3E; S24 Fig in S1 Appendix) .

Pathway analysis in severe vs. controls using GSEA found some moderate up-regulation of processes and cell components, but only phagocytic vesicle as under-regulated cellular component (S25 Fig in S1 Appendix) . Some of these pathways were also highlighted as up-regulated in severe vs. mild patients but, in this case, a positive regulation of cell migration and motility was also detected (S7 Table; (S29 Fig in S1 Appendix) . GSEA also pointed to a strong under-regulation of the IFN signalling in moderate vs.

mild cases in all the reference databases interrogated (S7 Table; Table; S30 Fig in S1 Appendix) .

We selected a subset of severe and mild patients (n = 21) with samples available from all tissues collected at the same time. We explored for interactions between severity and tissue to elucidate immunological features that could illuminate the causes for the differential evolution observed in patients. Only when relaxing the thresholds for this interaction analysis (adjusted P-value < 0.05 and a cumulative log2FC > |1.4|) we found that the effect of severity for the CXCL9 gene is significant for all tissue comparisons, being much lower in nasal compared to blood tissue (P-adjusted = 1.41E-6; cumulative log2FC = -2.94) and moderately lower for both saliva vs. blood (P-adjusted = 0.03; cumulative log2FC = -1.42) and nasal vs. saliva (P-adjusted = 0.017; cumulative log2FC = -1.51) tissues (S8 Table) . Looking at the CXCL9 normalized data, we found higher expression in severe than in mild cases for blood, with the opposite pattern in nasal and saliva epithelium samples (S31 Fig in S1 Appendix) . When we increased the significance thresholds (P-adjusted < 10E-6; cumulative log2FC > |2.5|) a set of 17 genes were found as DE in all possible comparisons (S8 Table; Fig 4B; Fig   4C) . Thirteen out of these 17 genes were also detected as DE between severe and mild cases in the longitudinal transcriptomic analysis (Fig 4B) . The transversal multi-tissue analysis generates four clusters for these 17 genes according to their cumulative Log2FC values (Fig 4C) . This analysis highlights that the main specific severity signals in blood were driven by gene cluster 1 represented by ARG1, CEACAM8, LTF and ITGA2B, and to a lesser extent by cluster 2 (specially IRAK3 and TLR5). This means that severity has a more marked effect in blood in comparison with nasal and saliva samples (Fig 4C; S8 Table; S31 Fig in S1 Appendix) . Cluster 3 (Fig 4C) , represented by CD22 and TRAF1, indicates that severity determines an opposite behavior in nasal (lower expression in mild and higher in severe) than in blood (higher expression in mild and lower in severe (S31 Fig in S1 Appendix) . Finally, cluster 4 (Fig 4C) represented by seven genes indicates a differential effect of severity in saliva with respect to blood and nasal epithelium (especially remarkable for MUC1 and

LGALS3). (83) . After viral interaction with ACE2 receptor, furin site in S protein of SARS-CoV-2 is proteolytically cleaved by TMPRSS2 to enable viral internalization (84) . Plasmin has demonstrated to cleave several viral proteins of many respiratory pathogens (85) (86) (87) and also S protein in SARS-CoV in vitro (88) , increasing the ability of the virus to enter host cells. Even though the plasmin protein S cleavage in SARS-CoC-2 has not been demonstrated, there is growing evidence pointing towards a probable role of the plasmin-plasminogen system and fibrinolytic pathway in the COVID-19 severity (89) (90) (91) (92) . Co-expression and upregulation of PLAU, TMPRSS2, and ACE2 was observed in airway epithelial cells from severe/moderate patients and SARS-CoV-2 infected cell lines. This, together with a plasmin-mediated cleavage, could make cells more susceptible to infection (93) . Interestingly, we also observed an enhanced expression of PLAU in nasal epithelium from severe cases when compared to mild and controls, highlighting the crosslink between both tissues. In the same vein, tetraspanins are molecules associated to specific viruses and seem to play a role in different stages of viral infections (94) . Tetraspanin CD9 was involved in early MERS-CoV lung cell entry (95) . Recently, it has also been proposed that extracellular vesicles may contribute to viral dissemination by transferring viral receptors, such as CD9 and ACE2, to other host cells making them more susceptible to the infection after exosomes endocytosis (96) . Our functional analysis revealed down-regulation of some pathways related to cell communication, adhesion and signal transduction in mild cases, probably as a mechanism to minimize viral spread. Conversely, severe cases showed up-regulation of genes involved in cell junction, adhesion and extracellular exosomes, all processes that could facilitate the viral dissemination. CD59 is a non-IFN inducible protein that acts as inhibitor of complement-mediated lysis by disruption of the membrane attack complex. Its implication in viral complement evasion of many enveloped viruses (97), including coronaviruses (98) , has been demonstrated. This escape mechanism can be mediated by incorporating CD59 to the viral envelope, controlling cellular CD59 expression or producing a counterpart protein that mimics host CD59, or even use it as cell entry receptor (99) . Overall, immune response in buccal cavity, due to its anatomical location and interplay between upper and lower respiratory tract (LRT), could play a key role in viral spread and transmission not only at interindividual level (37) but also in intra-individual viral dissemination to LRT, leading to a more severe phenotype.

Transversal analysis of different tissue samples from the same patients showed a tissue-specific behaviour depending on illness severity. Most of the tissue-specific severity signals observed were represented by genes involved in innate immune response and cytokine signaling. Genes that appeared differentially expressed with severities in nasal and blood samples are related to leukocyte chemotaxis, cytokine-cytokine signaling, cell adhesion and extracellular exosomes, with higher expression of severe cases (with respect to those with mild disease) in blood and, in contrast, lower expression in nasal samples; B-cell antigen receptor signaling genes showed an opposite pattern.

Specific differential signatures of severity in saliva samples correspond to genes involved in inflammatory and NK activation routes, cell adhesion, and vesicle trafficking.

Our results point to a set of genes and pathways that are tissue-specific and correlated to severity (Fig 5) ; many of these are involved in the innate immune system and cytokine/chemokine signaling pathways. Disease severity at systemic level might be strongly dependent on local immune response. Thus, the nasal epithelium shows a robust activation of the antiviral immune machinery in mild cases, characterized by IFN pathway involvement, thus triggering the IFN induced genes, chemokine release and transduction signaling in the cells, leading to the activation of downstream cascades related to Th1, NK and Tcytotoxic adaptative immune response. Instead, severe cases showed these local antiviral reactions switched off; they develop an exacerbated innate response represented by an over-expression of genes related to monocytemacrophage recruitment in nasal epithelium (Fig 5) . We did not find signals of immune viral response in buccal mucosa in mild patients, which probably indicates a successful local control of the infection and, therefore, prevention of viral dissemination and systemic colonization. On the contrary, buccal mucosa in moderate and, to a greater extent, severe cases, provided evident signals of viral activity, cell arresting and viral dissemination to the LRT (Fig 5) ; ultimately generating an exacerbated innate and impaired adaptative systemic immune responses. In addition, the buccal cavity might play a key role in body infection dissemination: a severe phenotype seems to be associated to limited immunological resistance to the virus in the mouth, therefore facilitating the dissemination of the virus towards the LRT. This could make saliva not only a good prognostic proxy of severity, but also a source of therapeutic targets to contain viral dissemination in early stages of the disease.

Overall, our findings include transcript biomarkers and pathways that signal severity at different tissue layers, and might illuminate new diagnostic, prognostic or therapeutic targets in COVID-19. Further validation using additional cohorts should be warranted.

AS and FMT conceived, designed, and provided financial support to the study. categories in saliva samples. Only genes with a log2FC |>1| were represented. 35 Gene clusters were generated using k-means partitioning. E) Upsetplot of the 36 common DEGs between categories compared in saliva samples. Bubble plot 37 represents log2FC and adjusted P-value from the 18 DEGs between severe and 38 all remaining categories. Green color in gene names indicates genes also 39 included in the hospitalized signature. well as in the multi-tissue transversal analysis. C) Heatmap and cluster analysis 44 of the DEGs between severities (severe/mild) and different tissue samples 45 (thresholds: P-adjusted = 10E-6, cumulative log2FC = |2.5|). Gene clusters were 46 generated using k-means partitioning. 

BI-BACVIR (PRIS-3; Agencia de Conocimiento en Salud (ACIS)-Servicio Gallego de Salud (SERGAS)-Xunta de Galicia; Spain)

Axencia Galega de Innovación (GAIN; IN607B 2020/08-Xunta de Galicia

PI16/01569/Cofinanciado FEDER)

PI19/01090/Cofinanciado FEDER), and Axencia Galega de Innovación

IN845D 2020/23-Xunta de Galicia

Mapping genome variation of SARS-CoV-2 worldwide highlights the impact of COVID-19 superspreaders

Assessing uncertainty in the rooting of the SARS-CoV-2 phylogeny

Estimated transmissibility and impact of SARS-CoV-2

Phylogeography of SARS-CoV-2 pandemic in Spain: a story of multiple introductions, micro-geographic stratification, founder effects, and super-spreaders

Superspreading events in the transmission dynamics of SARS-CoV-2: Opportunities for interventions and control

Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events

CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Temporal dynamics in viral shedding and transmissibility of COVID-19

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

SARS-CoV-2 productively infects human gut enterocytes

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy

Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status

Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19

Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection

Is FURIN gene expression in salivary glands related to SARS-CoV-2 infectivity through saliva?

Detection of SARS-CoV-2 in saliva and characterization of oral symptoms in COVID-19 patients

SARS-CoV-2 infection of the oral cavity and saliva

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

Assess the Stability of Candidate Housekeeping Genes. version 101, R package

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Normalization of RNA-seq data using factor analysis of control genes or samples

An approach for normalization and quality control for NanoString RNA expression data

EnhancedVolcano: Publication-ready volcano plots with enhanced colouring and labeling. version 180, R package

Complex heatmaps reveal patterns and correlations in multidimensional genomic data

Elegant Graphics for Data Analysis

Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles

clusterProfiler: an R package for comparing biological themes among gene clusters

enrichplot: Visualization of Functional Enrichment Result

Shared and organism-specific host responses to childhood diarrheal diseases revealed by whole blood transcript profiling

lumi: a pipeline for processing Illumina microarray

A framework for oligonucleotide microarray preprocessing

A 2-transcript host cell signature distinguishes viral from bacterial diarrhea and it is influenced by the severity of symptoms

Robust classification of bacterial and viral infections via integrated host gene expression diagnostics

limma powers differential expression analyses for RNA-sequencing and microarray studies

Determining cell type abundance and expression from bulk tissues with digital cytometry

Robust enumeration of cell subsets from tissue expression profiles

Regulation of antiviral T cell responses by type I interferons

Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV

Antiviral activities of type I interferons to SARS-CoV-2 infection

Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Vascular occlusion by neutrophil extracellular traps in COVID-19

SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology

The Emerging Role of

SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans

The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing

Profiling the Course of Resolving vs. Persistent Inflammation in Human Monocytes: The Role of IL-1 Family Molecules

Exploring NAD+ metabolism in host-pathogen interactions

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis

Antiviral Response in the Nasopharynx Identifies Patients With Respiratory Virus Infection

Syncytia formation by SARS-CoV-2-infected cells

The role of galectins in virus infection -A systemic literature review

The role of galectin-3 in promotion of the inflammatory response

Enhances Avian H5N1 Influenza A Virus-Induced Pulmonary Inflammation by Promoting NLRP3 Inflammasome Activation

Immunopathology of galectin-3: an increasingly promising target in COVID-19

Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3

Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis

ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome

Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis

Plasminogen-binding activity of neuraminidase determines the pathogenicity of influenza A virus

Enhancement of respiratory syncytial virusinduced cytopathology by trypsin, thrombin, and plasmin

Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro

Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility

COVID-19 and pneumonia: a role for the uPA/uPAR system

The Central Role of Fibrinolytic Response in COVID-19-A Hematologist's Perspective

Fibrinolysis influences SARS-CoV-2 infection in ciliated cells

Tetraspanins in viral infections: a fundamental role in viral biology?

The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases

The role of extracellular vesicles in COVID-19 virus infection

Relative Contribution of Cellular Complement Inhibitors CD59, CD46, and CD55 to Parainfluenza Virus 5 Inhibition of Complement-Mediated Neutralization

CD59 association with infectious bronchitis virus particles protects against antibody-dependent complement-mediated lysis

Interactions of viruses and the humoral innate immune response

This study received support from projects: GePEM (Instituto de Salud Carlos 

The authors declare that there are no competing interests.